Corvus Pharmaceuticals IPO Research Information

Corvus Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Corvus Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Corvus Pharmaceuticals	CRVS - NASDAQ	$15.00-$17.00	$15.00	$15.00	4.7 million	3/23/2016
Underwriter(s): Credit Suisse, Cowen & Co., Guggenheim Securities
Co-Manager(s): Cantor Fitzgerald & Co., BTIG
Industry: Health Care
Filing(s): Filed 2016-01-04 Terms Added 2016-03-10

Corvus Pharmaceuticals Quote & Chart - Click for current quote - CRVS

About Corvus Pharmaceuticals (adapted from Corvus Pharmaceuticals prospectus):
They are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "CRVS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.